Background: Histiocytoses represent a large, puzzling group of diseases which may involve the skin and other organs. At present, juvenile xanthogranuloma is the disorder most often confused with Langerhans cell histiocytosis. A complex overlap exists between juvenile xanthogranuloma and Langerhans cell histiocytosis, with lesions showing clinical and/or pathological features of both disorders. Observations: We report 2 patients affected by Langerhans cell histiocytosis who, during chemotherapy, presented cutaneous lesions with clinical and histological features of juvenile xanthogranuloma. During the therapy, in both cases, histological examination of new biopsies revealed the presence of Touton giant cells in the dermis with a few histiocytic cells; immunohistochemical staining was negative for CD1a, and no Birbeck granules were seen by ultrastructural examination. Results and Conclusion: A possible explanation for the link between Langerhans cell histiocytosis and juvenile xanthogranuloma regards the lineage development and the relationships of histiocytes. We suggest that chemotherapy can modify the production of cytokines by influencing the conversion or ‘maturation’ of pathological cells into macrophages or xanthomatous cells and fusing them to form multinucleated giant Touton cells. In our opinion, the modification of the cutaneous lesions during chemotherapy in Langerhans cell histiocytosis patients, as observed in our cases, could be a favorable prognostic factor.

Keywords:
Langerhans cell histiocytosis, Juvenile xanthogranuloma, Xanthohistiocytosis
1.
Lichtenstein L: Histiocytosis X: Integration of eosinophilic granuloma of bones, Letterer-Siwe disease and Schüller-Christian disease related manifestations of a single nosologic entity. Arch Pathol Lab Med 1953;56:84–102.
2.
Nezelof C, Basset F, Rousseau MF: Histiocytosis X: Histogenetic arguments for a Langerhans cell origin. Biomedicine 1973;18:365–371.
3.
Winkelmann RK: Cutaneous syndromes of non-X histiocytosis – A review of the macrophage-histiocyte diseases of the skin. Arch Dermatol 1981;117:667–672.
4.
Cline MJ: Histiocytes and histiocytoses. Blood 1994;84:2840–2853.
5.
Schmitz L, Favara BE: Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:221–246.
6.
Arceci RJ: The histiocytoses: The fall of the Tower of Babel. Eur J Cancer 1999;35:747–767, discussion 767–769.
7.
Favara BE, Jaffe R: The histopathology of Langerhans cell histiocytosis. Br J Cancer 1994;23(suppl):S17–S23.
8.
Munn S, Chu AC: Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am 1998;12:269–286.
9.
Singh A, Prieto VG, Czelusta A, McClain KL, Duvic M: Adult Langerhans cell histiocytosis limited to the skin. Dermatology 2003;207:157–161.
10.
Writing Group of the Histiocyte Society: Histiocytosis syndromes in children. Lancet 1987;i: 208–209.
11.
Roper SS, Spraker MK: Cutaneous histiocytosis syndromes. Pediatr Dermatol 1985;3:19–30.
12.
Gianotti F, Caputo R: Histiocytic syndromes: A review. J Am Acad Dermatol 1985;13:383–404.
13.
Esterly NB, Maurer HS, Gonzalez-Crussi F: Histiocytosis X: A seven-year experience at a children’s hospital. J Am Acad Dermatol 1985;13:481–496.
14.
Wood GS, Hu CH, Beckstead JH, Turner RR, Winkelmann RK: The indeterminate cell proliferative disorder: Report of a case manifesting as an unusual cutaneous histiocytosis. J Dermatol Surg Oncol 1985;11:1111–1119.
15.
Kolde G, Brocker EB: Multiple skin tumors of indeterminate cells in an adult. J Am Acad Dermatol 1986;15:591–597.
16.
Andersen WK, Knowles DM, Silvers DN: CD1 (OKT6)-positive juvenile xanthogranuloma: OKT6 is not specific for Langerhans cell histiocytosis (histiocytosis X). J Am Acad Dermatol 1992;26:850–854.
17.
Shani-Adir A, Chou P, Morgan E, Mancini AJ: A child with both Langerhans and non-Langerhans cell histiocytosis. Pediatr Dermatol 2002;19:419–422.
18.
Altman J, Winkelmann RK: Xanthomatous cutaneous lesions of histiocytosis X. Arch Dermatol 1963;87:164–170.
19.
Caputo R, Gelmetti C, Ermacora E, et al: Xanthomatous cutaneous lesions in patients affected by histiocytosis X. Jpn J Dermatol 1988;7:14–20.
20.
Caputo R, Grimalt R, Laterza A, et al: Muco-cutaneous expression of Langerhans cell histiocytosis in adults. Eur J Dermatol 1994;4:528–531.
21.
Hoeger PH, Diaz C, Manolet M, et al: Juvenile xanthogranuloma as a sequel to Langerhans cell histiocytosis: A report of three cases. Clin Exp Dermatol 2001;26:391–394.
22.
Chu AC: The confusing state of the histiocytoses. Br J Dermatol 2000;143:475–476.
23.
Caputo R: Histiocytoxanthomatosis. J EADV 2002;16(suppl 1):11.
24.
Caputo R, Ermacora E, Gelmetti C, Gianni E: Fatal nodular xanthomatosis in an infant. Pediatr Dermatol 1987;4:242–246.
25.
Yu Y, Tang L, Wang J, Liu S, Wang W, An H, Qi R, Zhang M, Cao X: Psoriatic lesional keratinocytes promote the maturation of human monocyte-derived Langerhans cells. Dermatology 2002;204:94–99.
26.
Chu T: Langerhans cell histiocytosis. Australas J Dermatol 2001;42:237–242.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.